drugset / Trial / NCT04116112
Blood Pressure After Endovascular Stroke Therapy-II
Phase 2
Completed
120 enrolled
University of Cincinnati
National Institute of Neurological Disorders and Stroke (NINDS) · collabVanderbilt University Medical Center · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to assess the safety of lowering blood pressure in acute stroke patients that are successfully treated with a mechanical thrombectomy procedure. The investogators will evaluate the hypothesis that lower blood pressure management strategies do not result in larger volume of stroke or worse 3-month clinical outcome in these patients.
Timeline
- Start
- 2020-01-17
- Primary completion
- 2022-07-01
- Completion
- 2022-12-15
Publications
- Mistry EA, Hart K, Davis T, Yeatts S, Lindsell CJ, Lewis RJ, Albers G, Wanderer JP, Prestigiacomo C, Bernard GR, Khatri P. Design of the BEST-II Randomized Clinical Trial. Stroke Vasc Interv Neurol. 2022 May 5;2(3):e000249. doi: 10.1161/SVIN.121.000249. eCollection 2022 May.
- Mistry EA, Hart KW, Davis LT, Gao Y, Prestigiacomo CJ, Mittal S, Mehta T, LaFever H, Harker P, Wilson-Perez HE, Beasley KA, Krothapalli N, Lippincott E, Stefek H, Froehler M, Chitale R, Fusco M, Grossman A, Shirani P, Smith M, Jaffa MN, Yeatts SD, Albers GW, Wanderer JP, Tolles J, Lindsell CJ, Lewis RJ, Bernard GR, Khatri P. Blood Pressure Management After Endovascular Therapy for Acute Ischemic Stroke: The BEST-II Randomized Clinical Trial. JAMA. 2023 Sep 5;330(9):821-831. doi: 10.1001/jama.2023.14330.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Hydralazine | Small molecule | — | — |
| Background | Labetalol | Small molecule | 10 mg | Intravenous |
| Background | Labetalol | Small molecule | 20 mg | Intravenous |
| Background | Nicardipine | Small molecule | 2.5 mg | Intravenous |